Compact LINAC for proton therapy

Published : Apr 26, 2017 12:30 IST

CERN researchers have designed a compact linear accelerator suitable for proton therapy applications.

PROTON and ion therapies are the preferred treatment for many cancers, such as tumours that are deep within the body. All of the nearly 100 worldwide facilities that offer this treatment use cyclotrons or synchrotrons to accelerate the charged particles to the necessary energies. Compared with these circular machines, linear accelerators (LINACs) offer certain advantages, but in addition to several design challenges, their large footprint is difficult to accommodate in hospitals.

Stefano Benedetti and colleagues from CERN, the European Centre for Particle Physics in Geneva, Switzerland, have designed a compact room-sized linear design that overcomes this size problem.

What makes LINACs preferable to circular accelerators is that the energies of their output beams can be adjusted rapidly (in milliseconds) and without loss of beam intensity. The beam energy determines how deeply the protons or ions will penetrate into tissue. This is useful for adjusting the beam position within the body as the patient breathes or to precisely hit different spots on a tumour.

Over the last few decades, researchers have explored various LINAC schemes. One of these, known as TULIP, coupled a LINAC to a cyclotron and achieved a compact footprint by winding a segment of the accelerator around the patient area. Benedetti and colleagues have conceptualised an “all-LINAC” version of TULIP that eliminates some of the technical complications of the hybrid model. Their design builds on developments such as improved radio-frequency technologies for injecting the particles into the machine and for accelerating them, and new particle-tracking methods. The new version would deliver protons capable of penetrating 33 centimetres into tissue, a figure on a par with that of existing designs, and would fit in a 10x20 metre room.

You have exhausted your free article limit.
Get a free trial and read Frontline FREE for 15 days
Signup and read this article for FREE

More stories from this issue

Get unlimited access to premium articles, issues, and all-time archives